Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.41 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790953 | 0.88 | ALDH1A1 (0.41) | RAB9ANPC1ALDH1A1KDM4ETSHR | |
| SCHEMBL6795740 | 0.83 | SOST (0.50) | ACACBSOST | |
| SCHEMBL31017536 | 0.81 | PTPN11 (0.48) | RAB9ANPC1 | |
| SCHEMBL6789803 | 0.81 | PTPN11 (0.48) | RAB9ANPC1 | |
| SCHEMBL6408537 | 0.75 | HPGD (0.41) | RAB9ANPC1ALDH1A1KDM4ETSHR | |
| SCHEMBL4764055 | 0.75 | GBA1 (0.43) | RAB9ANPC1ALDH1A1KDM4EGBA1 | |
| SCHEMBL4521816 | 0.75 | ALDH1A1 (0.37) | RAB9ANPC1ALDH1A1KDM4ETSHR | |
| SCHEMBL4764093 | 0.72 | KDM4E (0.35) | RAB9ANPC1ALDH1A1KDM4ETSHR | |
| SCHEMBL15819917 | 0.71 | NPSR1 (0.51) | RAB9ANPC1ALDH1A1KDM4ETSHR | |
| SCHEMBL29756638 | 0.71 | GRM5 (0.43) | RAB9ANPC1ALDH1A1KDM4EGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706885-B2 | HYDROGENATION OF PROTECTED 2,5-DI-(3'-AMINOPROP-1-YNYL) PYRIDINES AND DEPROTECTING TO FORM 2,5-DI-(3'-AMINOPROPYL)-PYRIDINES | MERCK & CO., INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030004353-A1 | Process for preparing integrin antagonist intermediates | MERCK SHARP & DOHME CORP. | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004353-A1 | Process for preparing integrin antagonist intermediates | ITGA5, ITGAV, ITGA2 | ACACB 4138/4885SOST 2187/4885RAB9A 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.